Practice guidelines for the management of infectious diarrhea

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 331-351

  Guerrant, Richard L ^a   Van Gilder, Thomas ^b   Slutsker, Laurence ^b   Tauxe, Robert V ^b   Hennessy, Thomas ^b   Griffin, Patricia M ^b   Pickering, Larry K ^b   Steiner, Ted S ^c   Thielman, Nathan M ^d   DuPont, Herbert ^e   Bradley Sack, R ^f   Tarr, Phillip ^g   Neill, Marguerite ^h   Nachamkin, Irving ⁱ   Reller, L Barth ^d   Osterholm, Michael T ^j   Bennish, Michael L ^k  

^a UNIVERSITY OF VIRGINIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DUKE UNIVERSITY   (United States)

^e St Luke's Episcopal Hospital   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g Children's Hospital and Medical Center   (United States)

^h MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Infect Control Advisory Network Inc   (United States)

^k TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; AZITHROMYCIN; CEFTRIAXONE; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DIIODOHYDROXYQUIN; DOXYCYCLINE; ELECTROLYTE; ERYTHROMYCIN; FOSFOMYCIN; GLUCOSE; GLUTAMINE; LACTOFERRIN; MACROLIDE; METRONIDAZOLE; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; ORAL REHYDRATION SOLUTION; PAROMOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOL; TOXIN; TYPHOID VACCINE; UNINDEXED DRUG; ZINC;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; CAMPYLOBACTER JEJUNI; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CONTRAINDICATION; ESCHERICHIA COLI; FECES CULTURE; FLUID THERAPY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION CONTROL; ORAL REHYDRATION THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SHIGELLOSIS; TRAVELLER DIARRHEA; TYPHOID FEVER;

ANTI-INFECTIVE AGENTS; ANTIDIARRHEALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; FECES; FLUID THERAPY; HUMANS; PUBLIC HEALTH;

EID: 0035118034     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318514     Document Type: Review

References (223)

1. Purpose of quality standards for infectious diseases
2. Community-acquired pneumonia in adults: Guidelines for management
3. Why America must care about tropical medicine: Threats to global health and security from tropical infectious diseases
4. Population-based estimate of the burden of diarrheal illnesses: FoodNet 1996-1997
5. Prevalence of major digestive disorders and bowel symptoms, 1989
6. Food-related illness and death in the United States
7. Campylobacter species and Guillain-Barre syndrome
8. Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells
9. Effects of Cryptosporidium parvum infection in Peruvian children: Growth faltering and subsequent catch-up growth
10. Asymptomatic and symptomatic cryptosporidiosis: Their acute effect on weight gain in Peruvian children
11. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function 4-7 years later in a poor urban community in Northeast Brazil
12. Estimates of incidence and costs of intestinal infectious diseases in the United States
13. Variations in stool handling and culturing practices among clinical microbiology laboratories within the Foodborne Active Surveillance Network (FoodNet): Do we need practice guidelines?
14. Diarrhea in developed and developing countries: Magnitude, special settings, and etiologies
15. Diarrhoeal diseases in the White Mountain Apaches: Epidemiologic studies
16. Diarrhoeal diseases in the White Mountain Apaches: Clinical studies
17. Diarrheal illness among infants and toddlers in day care centers. II. Comparison with day care homes and households
18. Acute gastrointestinal illness and child care arrangements
19. Child day care increases the risk of clinic visits for acute diarrhea and diarrhea due to rotavirus
20. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. I. Patterns of morbidity
21. Prospective study of diarrheal illnesses in northeastern Brazil: Patterns of disease, nutritional impact, etiologies, and risk factors
22. A prospective study of persistent diarrhea among children in an urban Brazilian slum
23. Diarrheal deaths in American children: Are they preventable?
24. Guidelines on acute infectious diarrhea in adults
25. Hospitalizations involving gastroenteritis in the United States, 1985: The special burden of the disease among the elderly
26. Estimates of morbidity and mortality rates for diarrheal diseases in American children
27. Diarrheal deaths in the United States, 1979 through 1987: A special problem for the elderly
28. Value of stool cultures
29. A cost effective and effective approach to the diagnosis and management of acute infectious diarrhea
30. Evaluation and diagnosis of acute infectious diarrhea
31. Practice guidelines for ordering stool cultures in a pediatric population
32. Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhea in a community hospital
33. Acute infectious diarrhea
34. A national outbreak of Salmonella enteritidis infections from ice cream
35. A review of human salmonellosis: III. Magnitude of salmonella infection in the United States
36. Effective use of the clinical microbiology laboratory for diagnosing diarrheal diseases
37. Escherichia coli O157:H7 and the hemolytic-uremic syndrome
38. Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli
39. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice
40. Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7
41. Escherichia coli O157: H7 hemorrhagic colitis
42. Characterization of Escherichia coli serotype O157:H7
43. Illnesses associated with Escherichia coli 0157:H7 infections: A broad clinical spectrum
44. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: Clinical and epidemiologic observations
45. The expression of blood group P1 in post-enteropathic haemolytic uraemic syndrome
46. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome
47. Infections with Escherichia coli O157:H7 in Washington State: The first year of statewide disease surveillance
48. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis
49. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections
50. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection
51. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: Experience during and outbreak in health care workers
52. Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo
53. Drug-resistant Salmonella from animals fed antimicrobials
54. Drug-resistant Salmonella in the United States: An epidemiologic perspective
55. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella
56. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
57. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea
58. A severe outbreak of Escherichia coli O157:HT-associated hemorrhagic colitis in a nursing home
59. How safe is our food? Lessons from an outbreak of salmonellosis
60. Changing epidemiology of food-borne disease: A Minnesota perspective
61. Why foodborne disease surveillance is critical to the safety of our food supply
62. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States
63. Contemporary testing for enteric pathogens: The potential for cost, time, and health care savings
64. Application of rejection criteria for stool ovum and parasite examinations
65. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults
66. Inappropriate testing for diarrheal diseases in the hospital
67. To culture or not to culture: Fecal lactoferrin screening for inflammatory bacterial diarrhea
68. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children
69. Escherichia coli O157:H7 diarrhea in the United States: Clinical and epidemiologic features
70. Escherichia coli O157:H7, an emerging gastrointestinal pathogen: Results of a one-year, prospective, population-based study
71. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States
72. Escherichia coli O157-H7
73. Perspective: The problem of non-O157:H7 Shiga toxin (verocytotoxin)-producing Escherichia coli
74. Yersinia enterocolitica 0:3: An emerging cause of pediatric gastroenteritis in the United States
75. Fecal leukocytes in diarrheal illness
76. Bacterial and protozoal gastroenteritis
77. Value of examination for fecal leukocytes in the early diagnosis of shigellosis
78. A rapid test for infectious and inflammatory enteritis
79. Practice parameter: The management of acute gastroenteritis in young children
80. Oral maintenance therapy for cholera in adults
81. Effect of intragastric glucose-electrolyte infusion upon water and electrolyte balance in Asiatic cholera
82. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions
83. Water with sugar and salt
84. Oral therapy for acute diarrhea: The underused simple solution
85. Food-based oral rehydration salt solutions for acute childhood diarrhoea
86. Turning off the diarrhea: The role of food and ORS
87. Efficacy of a glutamine-based oral rehydration solution on the electrolyte and water absorption in a rabbit model of secretory diarrhea induced by cholera toxin
88. An algorithmic approach to the workup and management of HIV-related diarrhea
89. Diarrhea and AIDS in the era of highly active antiretroviral therapy
90. Clostridium difficile-associated diarrhea in human immunodeficiency virus infection: A changing scenario
91. Shigellosis in children from north India: A clinicopathological study
92. Occult blood versus fecal leukocytes in the diagnosis of bacterial diarrhea: A study of US travelers to Mexico and Mexican children
93. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin
94. Foodhandler-assodated Salmonella outbreak in a university hospital despite routine surveillance cultures of kitchen employees
95. Characteristics of Shigella sonnei infection of volunteers: Signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances
96. Diagnosis and management of dysentery by community health workers
97. Yersinia enterocolitica gastroenteritis: A prospective study of clinical bacteriologic and epidemiologic features
98. Microbiologic and clinical study of acute diarrhea in children in Aswan, Egypt
99. Differential clinical features and stool findings in shigellosis and amoebic dysentery
100. Association of Escherichia coli HEp-2 adherence patterns with type and duration of diarrhoea
101. Measurement of fecal lactoferrin for rapid diagnosis of enterohemorrhagic Escherichia coli infection
102. Foodborne outbreaks of enterotoxigenic Escherichia coli: Rhode Island and New Hampshire 1993
103. Evaluation of patients with chronic diarrhea
104. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin
105. Randomized clinical trial of norfloxacin for shigellosis
106. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial
107. Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt
108. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial
109. Double-blind placebo-controlled trial of erythromycin in the treatment of clinical Campylobacter infection
110. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children
111. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998
112. Quinolone resistance and Campylobacter species
113. Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC
114. High-level quinolone resistance in clinical isolates of Campylobacter jejuni
115. Empiric treatment of acute diarrheal disease with norfloxacin: A randomized, placebo-controlled study
116. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults
117. Early treatment of Campylobacter jejuni enteritis
118. Erythromycin in treatment of Campylobacter enteritis in children
119. Antimicrobial-resistant Shigella: The growing need for prevention strategies
120. Antibiotics for Escherichia coli O157:H7 enteritis?
121. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome
122. Lessons learned in the management of hemolytic uremic syndrome in children
123. A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome
124. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections
125. Randomised double blind trial of single dose doxycycline for treating cholera in adults
126. The treatment of Giardia lamblia infection with mepacrine, metronidazole and furazolidone
127. Double-blind, randomized, controlled clinical trials of norfloxacin for cholera
128. Paromomycin: An effective treatment for cryptosporidial diarrhea in patients with AIDS
129. Clinical disease spectrum and pathogenic factors associated with Plesiomonas shigelloides infections in humans
130. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
131. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy
132. Yersinia enterocolitica
133. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome
134. Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: Response to therapy with albendazole
135. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone
136. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial
137. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis
138. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS
139. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy
140. Clostridium difficile-associated diarrhea and colitis
141. Ciprofloxacin for the treatment of cholera: A randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults
142. Placebo-controlled trial of co-trimoxazole for cyclospora infections among travellers and foreign residents in Nepal
143. Aeromonas hydrophila and Plesiomonas shigelloides as causes of intestinal infections
144. Plesiomonas enteric infections in the United States
145. Clinical features, epidemiology, and treatment of Plesiomonas shigelloides diarrhea
146. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults
147. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139
148. Treatment of giardiasis: Literature review and recommendations
149. Efficacy of various drugs for treatment of giardiasis. A comparative study
150. Epidemiology and treatment of Cyclospora cayetanensis infection in Peruvian children
151. Short-term treatment of traveler's diarrhea with norfloxacin: A double-blind, placebo-controlled study during two seasons
152. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: A randomized double-blind controlled trial
153. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: Clinical features and response to albendazole therapy
154. Ciprofloxacin and loperamide in the treatment of bacillary dysentery
155. Treatment of symptomatic enteric Aeromonas hydrophila infection with ciprofloxacin
156. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991
157. Clinical features of sporadic Yersinia enterocolitica infections in Norway
158. Placebo-controlled double-blind evaluation of trimethoprim-sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis
159. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis
160. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome
161. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of shigella and enteroinvasive Escherichia coli disease
162. Plesiomonas shigelloides-associated diarrhea
163. Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7
164. Hemorrhagic colitis associated with a rare Escherichia coli serotype
165. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica
166. Treatment of children with acute amoebic dysentery. Comparative trial of metronidazole against a combination of dehydroemetine, tetracycline, and diloxanide furoate
167. Trials with metronidazole in amebic dysentery
168. Antimicrobial resistance of Shigella isolates in the USA: The importance of international travelers
169. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis
170. Antibiotics in the treatment of gastroenteritis caused by enteropathogenic Escherichia coli
171. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea
172. Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus
173. Paromomycin for cryptosporidiosis in AIDS: A prospective, double-blind trial
174. Cholera vaccine
175. Typhoid immunization. Recommendations of the Immunization Practices Advisory Committee
176. New approaches to surveillance and control of emerging foodborne infectious diseases
177. An outbreak of Escherichia coli O157:H7 colitis associated with consumption of pre-cooked meat patties
178. Communitywide shigellosis: Control of an outbreak and risk factors in child day-care centers
179. Prevention and control of enterohaemorrhagic Escherichia coli (EHEC) infections: Memorandum from a WHO meeting. WHO consultation on prevention and control of enterohaemorrhagic Escherichia coli (EHEC) infections
180. Bacterial enteric infections in persons infected with human immunodeficiency virus
181. Typhoid fever vaccines: A meta-analysis of studies on efficacy and toxicity
182. The Tecumseh Study. XI. Occurrence of acute enteric illness in the community
183. Acute gastrointestinal illness in Charlottesville: A prospective family study
184. A university outbreak of Escherichia coli O157:H7 infections associated with roast beef and an unusually benign clinical course
185. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply
186. An outbreak in 1996 of cyclosporiasis associated with imported raspberries
187. Amebiasis in the United States
188. Comparison of fecal lactoferrin latex agglutination assay and methylene blue microscopy for detection of fecal leukocytes in Clostridium difficile-associated disease
189. Bacterial and protozoal gastroenteritis
190. Application of rejection criteria for stool cultures for bacterial enteric pathogens
191. Predictive value of stool examination in acute diarrhea
192. Escherichia coli O157:H7 and the hemolytic uremic syndrome: Importance of early cultures in establishing the etiology
193. Evaluation of a new latex agglutination test for fecal lactoferrin in travelers' diarrhea
194. Measurement of fecal lactoferrin as a marker of fecal leukocytes
195. Fecal lactoferrin, interleukin-1β, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis
196. Antimicrobial therapy for shigellosis
197. Treatment of multiresistant typhoid fever
198. Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone and other newer cephalosporins